6KL9 image
Entry Detail
PDB ID:
6KL9
EMDB ID:
Title:
Structure of LbCas12a-crRNA complex bound to AcrVA4 (form A complex)
Biological Source:
PDB Version:
Deposition Date:
2019-07-30
Release Date:
2019-09-11
Method Details:
Experimental Method:
Resolution:
3.25 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:LbCas12a
Chain IDs:A
Chain Length:1228
Number of Molecules:1
Biological Source:Lachnospiraceae bacterium
Polymer Type:polypeptide(L)
Description:AcrVA4
Chain IDs:B, C
Chain Length:234
Number of Molecules:2
Biological Source:Moraxella bovoculi
Polymer Type:polyribonucleotide
Description:RNA (42-MER)
Chain IDs:D (auth: G)
Chain Length:42
Number of Molecules:1
Biological Source:synthetic construct
Ligand Molecules
Primary Citation
Structural insight into multistage inhibition of CRISPR-Cas12a by AcrVA4.
Proc.Natl.Acad.Sci.USA 116 18928 18936 (2019)
PMID: 31467167 DOI: 10.1073/pnas.1909400116

Abstact

Prokaryotes possess CRISPR-Cas systems to exclude parasitic predators, such as phages and mobile genetic elements (MGEs). These predators, in turn, encode anti-CRISPR (Acr) proteins to evade the CRISPR-Cas immunity. Recently, AcrVA4, an Acr protein inhibiting the CRISPR-Cas12a system, was shown to diminish Lachnospiraceae bacterium Cas12a (LbCas12a)-mediated genome editing in human cells, but the underlying mechanisms remain elusive. Here we report the cryo-EM structures of AcrVA4 bound to CRISPR RNA (crRNA)-loaded LbCas12a and found AcrVA4 could inhibit LbCas12a at several stages of the CRISPR-Cas working pathway, different from other characterized type I/II Acr inhibitors which target only 1 stage. First, it locks the conformation of the LbCas12a-crRNA complex to prevent target DNA-crRNA hybridization. Second, it interacts with the LbCas12a-crRNA-dsDNA complex to release the bound DNA before cleavage. Third, AcrVA4 binds the postcleavage LbCas12a complex to possibly block enzyme recycling. These findings highlight the multifunctionality of AcrVA4 and provide clues for developing regulatory genome-editing tools.

Legend

Protein

Chemical

Disease

Primary Citation of related structures